세계의 Drug Discovery 아웃소싱 시장 - 규모, 점유율, 동향 분석 보고서 : 의약품 유형별, 워크플로우별, 치료 영역별, 서비스 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Small, Large Molecules), By Workflow, By Therapeutics Area, By Service Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

Drug Discovery 아웃소싱 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 Drug Discovery 아웃소싱 시장 규모는 2030년까지 102억 3,000만 달러에 이르며, 2025-2030년 동안 CAGR은 7.58%로 확대될 전망입니다. 신약은 비용과 시간이 많이 걸리는 과정입니다. 이러한 이유로 제약 회사와 생명 공학 회사는 연구 활동을 학술 기관 및 비공개 회사(CRO)에 아웃소싱하기로 선택했습니다. 공공기관과 민간기업간의 제휴 증가는 창약 프로세스를 가속화하여 창약을 위한 아웃소싱 서비스의 세계 수요가 증가하고 있습니다.

이 시나리오는 COVID 후에도 계속될 것으로 예상됩니다. 만성 질환 환자가 증가함에 따라 기업은 수명을 연장시키는 의약품의 개발을 강력히 요구하고 있습니다. 유엔에 따르면 2015-2020년 사이에 65세가 되는 사람의 수명은 17년 연장될 것으로 예상되고 있습니다. 기업이 아웃소싱에 적극적으로 노력하고 있는 주요 치료 영역에는 암, 순환기, 항감염제 등이 있습니다. 2020년 11월, AstraZeneca는 가장 치료하기 어려운 암 연구를 촉진하기 위해 9개의 주요 암 의료 센터와 제휴했습니다. 이 회사는 이 네트워크의 구성원의 임상 및 비임상 연구 제안에 자금을 제공할 예정입니다.

COVID-19의 대유행은 창약과 개발의 가치를 입증했습니다. 세계 사람들이 백신을 기다리고 있는 반면, 여러 기업이 COVID-19에 대항하는 효과적인 백신 개발에 적극적으로 노력하고 있습니다. Pfizer와 BioNTech SE는 이 바이러스와 싸울 수있는 균주의 3상 임상시험 후 백신의 최초 승인을 받았습니다. 임상 검사에 관해서는 대부분이 중단되었지만 원격 모니터링 기술을 채택하여 작동하는 것도 있습니다. 이와 같이 유행은 Drug Discovery 아웃소싱이 바이러스에 대한 효과적인 치료법을 개발하는 중요한 측면이 되어 제약 산업의 중심 무대를 가져왔습니다. 이 때문에 향후 2년간은 단기적인 붐으로 시장 수익을 끌어올려 그 이후는 본래의 성장 곡선을 되찾을 것으로 예상됩니다.

Drug Discovery 아웃소싱 시장 보고서 하이라이트

• 워크플로우 부문을 기반으로 시장은 대상 식별 및 스크리닝, 대상 검증 및 기능 정보, 리드 식별 및 후보 최적화, 전임상 개발 및 기타 관련 워크플로우로 구분됩니다.
• 치료 부문별로는 호흡기계, 통증·마취, 종양, 안과, 혈액, 순환기, 내분비, 소화기, 면역조절, 항감염, 중추신경, 피부, 비뇨생식기로 구분됩니다.
• 의약품 유형별로 시장은 저분자와 고분자(바이오의약품)로 구분됩니다.
• 서비스 유형별로 시장은 화학적 서비스와 생물학적 서비스로 구분됩니다. 화학 부문은 산업 전반에서 저분자 아웃소싱 프로젝트가 증가함에 따라 2024년 매출 점유율에서 최대를 차지했습니다.
• 최종 용도별로, 시장은 제약 및 바이오테크놀러지 기업, 학술기관, 기타로 구분됩니다. 2024년에는 제약 및 바이오테크놀러지 기업이 최대의 수익 점유율을 차지하고 시장을 독점했습니다.
• 아시아태평양 시장은 2024년에 45.99%의 최대 시장 점유율을 차지했습니다. 이러한 성장은 의료 지출 증가와 의약품 수요 증가 등 다양한 요인에 기인한 것으로 예상됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 Drug Discovery 아웃소싱 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• Drug Discovery 아웃소싱 시장 분석 도구
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 Drug Discovery 아웃소싱 시장 : 워크플로우별, 추정·동향 분석

• Drug Discovery 아웃소싱 시장, 워크플로우별 : 부문 대시보드
• Drug Discovery 아웃소싱 시장, 워크플로우별 : 변동 분석
• 워크플로우별, 2018-2030년
• 대상 식별 및 스크리닝
• 대상 검증 & 기능 정보학
• 리드 식별 및 후보 최적화
• 전임상 개발
• 기타

제5장 Drug Discovery 아웃소싱 시장 : 치료 영역별, 추정·동향 분석

• Drug Discovery 아웃소싱 시장, 치료 영역별: 부문 대시보드
• Drug Discovery 아웃소싱 시장, 치료 영역별: 변동 분석
• 치료 영역별, 2018-2030년
• 호흡기계
• 통증·마취
• 종양
• 안과
• 혈액
• 순환기
• 내분비
• 소화기
• 면역조절
• 항감염
• 중추신경
• 피부과
• 비뇨 생식기

제6장 Drug Discovery 아웃소싱 시장 : 의약품 유형별, 추정·동향 분석

• Drug Discovery 아웃소싱 시장, 의약품 유형별: 부문 대시보드
• Drug Discovery 아웃소싱 시장, 의약품 유형별 : 변동 분석
• 의약품 유형별, 2018-2030년
• 저분자
  • 저분자 시장, 2018-2030년,
• 고분자(바이오의약품)
  • 고분자(바이오의약품) 시장, 2018-2030년,

제7장 Drug Discovery 아웃소싱 시장 : 서비스 유형별, 추정·동향 분석

• Drug Discovery 아웃소싱 시장, 서비스 유형별: 부문 대시보드
• Drug Discovery 아웃소싱 시장, 서비스 유형별 : 변동 분석
• 서비스 유형별, 2018-2030년
• 화학 서비스
  • 화학적 서비스 시장, 2018-2030년,
• 생물학적 서비스
  • 생물학적 서비스 시장, 2018-2030년,

제8장 Drug Discovery 아웃소싱 시장 : 최종 용도별, 추정·동향 분석

• Drug Discovery 아웃소싱 시장, 최종 용도별: 부문 대시보드
• Drug Discovery 아웃소싱 시장, 최종 용도별 : 변동 분석
• 최종 용도별, 2018-2030년
• 제약 및 바이오테크놀러지 기업
  • 제약 및 바이오테크놀러지 기업 시장, 2018-2030년,
• 학술기관
  • 학술기관 시장, 2018-2030년,

제9장 Drug Discovery 아웃소싱 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 이탈리아
  • 프랑스
  • 스페인
  • 네덜란드
  • 벨기에
  • 스위스
  • 러시아
  • 스웨덴
• 아시아태평양
  • 중국
  • 일본
  • 호주
  • 한국
  • 인도
  • 태국
  • 말레이시아
  • 인도네시아
  • 싱가포르
  • 필리핀
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 콜롬비아
  • 칠레
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트
  • 이스라엘
  • 이집트

제10장 경쟁 구도

• 시장 진출기업의 분류
• 기업의 시장 점유율 분석, 2024년
• 기업 프로파일
  • Albany Molecular Research Inc.
  • EVOTEC
  • Laboratory Corporation of America Holdings
  • GenScript
  • Pharmaceutical Product Development, LLC
  • Charles River Laboratories
  • WuXi AppTec
  • Merck &Co., Inc.
  • Thermo Fisher Scientific Inc
  • Dalton Pharma Services
  • Oncodesign
  • Jubilant Biosys
  • DiscoverX Corp.
  • QIAGEN
  • Eurofins SE
  • Syngene International Limited
  • Dr. Reddy Laboratories Ltd.
  • Pharmaron Beijing Co., Ltd.
  • TCG Lifesciences Pvt Ltd.
  • Domainex Ltd.

JHS

영문 목차

영문목차

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 10.23 billion by 2030 and is expected to expand at a CAGR of 7.58% from 2025 to 2030, according to a new report by Grand View Research, Inc., The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

• On the basis of workflow segment, the market is segmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow.
• On the basis of therapeutics area segment, the market is segmented into Respiratory System, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective, Central Nervous System, Dermatology, and Genitourinary System.
• On the basis of drug type segment, the market is segmented into Small Molecules, and Large Molecules (Biopharmaceuticals).
• On the basis of service type segment, the market is segmented into Chemistry Services, and Biology Services. The chemistry segment dominated the market with the largest revenue share in 2024, owing to increasing number of outsourcing projects for small molecules across the industry.
• On the basis of end use segment, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. The pharmaceutical & biotechnology companies segment dominated the market with the largest revenue share in 2024.
• Asia Pacific market held the largest market share of 45.99% in 2024. This growth can be attributed to various factors, such as rising healthcare expenditure and growing demand for pharmaceutical products.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Therapeutics Area
  • 1.2.3. Drug type
  • 1.2.4. Service Type
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing R&D In Biopharmaceutical Industry
    • 3.2.1.2. Increasing demand for outsourcing Services in Drug Development
    • 3.2.1.3. Increasing number of partnerships in drug discovery research
    • 3.2.1.4. Technological advancements in drug discovery
    • 3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of open-source software packages for drug discovery
    • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
• 3.3. Drug Discovery Outsourcing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
• 4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
• 4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Other Associate Workflow
  • 4.8.1. Other Associate Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

• 5.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
• 5.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
• 5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics, 2018 - 2030
• 5.4. Respiratory System
  • 5.4.1. Respiratory System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Pain and Anesthesia
  • 5.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Oncology
  • 5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Ophthalmology
  • 5.7.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Hematology
  • 5.8.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Cardiovascular
  • 5.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Endocrine
  • 5.10.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Gastrointestinal
  • 5.11.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Immunomodulation
  • 5.12.1. Immunomodulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.13. Anti-Infective
  • 5.13.1. Anti-Infective Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.14. Central Nervous System
  • 5.14.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.15. Dermatology
  • 5.15.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.16. Genitourinary System
  • 5.16.1. Genitourinary System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis

• 6.1. Drug Discovery Outsourcing Market, By Drug Type: Segment Dashboard
• 6.2. Drug Discovery Outsourcing Market, By Drug Type: Movement Analysis
• 6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
• 6.4. Small Molecules
  • 6.4.1. Small Molecules Market, 2018 to 2030, (USD Million)
• 6.5. Large Molecules (Biopharmaceuticals)
  • 6.5.1. Large Molecules (Biopharmaceuticals) Market, 2018 to 2030, (USD Million)

Chapter 7. Drug Discovery Outsourcing Market: Service Type Estimates & Trend Analysis

• 7.1. Drug Discovery Outsourcing Market, By Service Type: Segment Dashboard
• 7.2. Drug Discovery Outsourcing Market, By Service Type: Movement Analysis
• 7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service Type, 2018 - 2030
• 7.4. Chemistry Services
  • 7.4.1. Chemistry Services Market, 2018 to 2030, (USD Million)
• 7.5. Biology Services
  • 7.5.1. Biology Services Market, 2018 to 2030, (USD Million)

Chapter 8. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
• 8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
• 8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 8.4. Pharmaceutical & Biotechnology companies
  • 8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 to 2030, (USD Million)
• 8.5. Academic Institutes
  • 8.5.1. Academic Institutes Market, 2018 to 2030, (USD Million)

Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. North America
  • 9.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. U.S
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Europe
  • 9.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. Italy
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. France
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Netherland
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Netherland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.8. Belgium
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Competitive Scenario
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.9. Switzerland
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Competitive Scenario
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.10. Russia
    • 9.5.10.1. Key Country Dynamics
    • 9.5.10.2. Competitive Scenario
    • 9.5.10.3. Regulatory Framework
    • 9.5.10.4. Russia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.11. Sweden
    • 9.5.11.1. Key Country Dynamics
    • 9.5.11.2. Competitive Scenario
    • 9.5.11.3. Regulatory Framework
    • 9.5.11.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. China
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Japan
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. Australia
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. South Korea
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.6. India
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Competitive Scenario
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Competitive Scenario
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.8. Malaysia
    • 9.6.8.1. Key Country Dynamics
    • 9.6.8.2. Competitive Scenario
    • 9.6.8.3. Regulatory Framework
    • 9.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.9. Indonesia
    • 9.6.9.1. Key Country Dynamics
    • 9.6.9.2. Competitive Scenario
    • 9.6.9.3. Regulatory Framework
    • 9.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.10. Singapore
    • 9.6.10.1. Key Country Dynamics
    • 9.6.10.2. Competitive Scenario
    • 9.6.10.3. Regulatory Framework
    • 9.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.11. Philippines
    • 9.6.11.1. Key Country Dynamics
    • 9.6.11.2. Competitive Scenario
    • 9.6.11.3. Regulatory Framework
    • 9.6.11.4. Philippines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.7. Latin America
  • 9.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. Colombia
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Chile
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.8. MEA
  • 9.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Competitive Scenario
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Competitive Scenario
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Competitive Scenario
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Competitive Scenario
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.6. Israel
    • 9.8.6.1. Key Country Dynamics
    • 9.8.6.2. Competitive Scenario
    • 9.8.6.3. Regulatory Framework
    • 9.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8.7. Egypt
    • 9.8.7.1. Key Country Dynamics
    • 9.8.7.2. Competitive Scenario
    • 9.8.7.3. Regulatory Framework
    • 9.8.7.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Company Market Share Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Albany Molecular Research Inc.
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. EVOTEC
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Laboratory Corporation of America Holdings
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. GenScript
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Pharmaceutical Product Development, LLC
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. Charles River Laboratories
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. WuXi AppTec
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Merck & Co., Inc.
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Thermo Fisher Scientific Inc
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Dalton Pharma Services
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. Oncodesign
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives
  • 10.3.12. Jubilant Biosys
    • 10.3.12.1. Company Overview
    • 10.3.12.2. Financial Performance
    • 10.3.12.3. Service Benchmarking
    • 10.3.12.4. Strategic Initiatives
  • 10.3.13. DiscoverX Corp.
    • 10.3.13.1. Company Overview
    • 10.3.13.2. Financial Performance
    • 10.3.13.3. Service Benchmarking
    • 10.3.13.4. Strategic Initiatives
  • 10.3.14. QIAGEN
    • 10.3.14.1. Company Overview
    • 10.3.14.2. Financial Performance
    • 10.3.14.3. Service Benchmarking
    • 10.3.14.4. Strategic Initiatives
  • 10.3.15. Eurofins SE
    • 10.3.15.1. Company Overview
    • 10.3.15.2. Financial Performance
    • 10.3.15.3. Service Benchmarking
    • 10.3.15.4. Strategic Initiatives
  • 10.3.16. Syngene International Limited
    • 10.3.16.1. Company Overview
    • 10.3.16.2. Financial Performance
    • 10.3.16.3. Service Benchmarking
    • 10.3.16.4. Strategic Initiatives
  • 10.3.17. Dr. Reddy Laboratories Ltd.
    • 10.3.17.1. Company Overview
    • 10.3.17.2. Financial Performance
    • 10.3.17.3. Service Benchmarking
    • 10.3.17.4. Strategic Initiatives
  • 10.3.18. Pharmaron Beijing Co., Ltd.
    • 10.3.18.1. Company Overview
    • 10.3.18.2. Financial Performance
    • 10.3.18.3. Service Benchmarking
    • 10.3.18.4. Strategic Initiatives
  • 10.3.19. TCG Lifesciences Pvt Ltd.
    • 10.3.19.1. Company Overview
    • 10.3.19.2. Financial Performance
    • 10.3.19.3. Service Benchmarking
    • 10.3.19.4. Strategic Initiatives
  • 10.3.20. Domainex Ltd.
    • 10.3.20.1. Company Overview
    • 10.3.20.2. Financial Performance
    • 10.3.20.3. Service Benchmarking
    • 10.3.20.4. Strategic Initiatives

관련자료